DOCSLIB.ORG

Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St Burden of serious fungal infections in Jamaica UHSM ¤ 1,2* University Hospital Harish Gugnani , David W Denning of South Manchester NHS Foundation Trust ¤Professor of Microbiology & Epidemiology, St. James School of Medicine, Kralendjik, Bonaire (Dutch Caribbean). 1 LEADING WI The University of Manchester, Manchester Academic Health Science Centre, Manchester, U.K. INTERNATIONAL 2 FUNGAL The University Hospital of South Manchester, (*Corresponding Author) National Aspergillosis Centre (NAC) Manchester, U.K. EDUCATION Background and Rationale The incidence and prevalence of fungal infections in Jamaica is unknown. The first human case of Conidiobolus coronatus infection was discovered in Jamaica (Bras et al. 1965). Cases of histoplasmosis and eumycetoma are reported (Fincharn & DeCeulaer 1980, Nicholson et al., 2004; Fletcher et al, 2001). Tinea capitis is very frequent in children Chronic pulmonary (East-Innis et al., 2006), because of the population being aspergillosis with aspergilloma (in the left upper lobe) in a 53- predominantly of African ancestry. In a one year study of 665 HIV yr-old, HIV-negative Jamaican male, developing after one infected patients, 46% of whom had CD4 cell counts <200/uL, 23 had year of antitubercular treatment; his baseline IgG pneumocystis pneumonia and 3 had cryptococcal meningitis (Barrow titer was 741 mg/L (0-40). As a smoker, he also had moderate et al. 2010). We estimated the burden of fungal infections in Jamaica emphysema. from published literature and modelling. Table 1. Estimated burden of fungal disease in Jamaica Fungal None HIV Respiratory Cancer ICU Total Rate Methods condition /AIDS /Tx burden 100k We also extracted data from published papers on epidemiology and Oesophageal ? 2,100 - ? - 2,100 77 from the WHO STOP TB program and UNAIDS. Where no data existed, candidiasis we used specific populations at risk and fungal infection frequencies in Candidaemia - - - 95 41 136 5 Candida - ? - - 20 20 0.75 those populations to estimate national incidence or prevalence. Chronic peritonitis pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis RVVC (4x/year+) 42,885 - - - - 42,885 3,154 ABPA, severe asthma with fungal sensitisation (SAFS) rates were based on asthma and TB rates. Asthma rates (doctor diagnosed asthma) in ABPA - - 13,050 - - 13,050 480 13-14 year olds were taken from Kahwa et al, (BMJ Open, 2012) and SAFS - - 17,225 - - 17,225 633 assumed to relate to adulthood. Other assumptions were based on CPA - - 82 - - 82 11.2 incidence rates reported in the local and international literature. The IA - - - ? ? ? denominator included the overall Jamaican population, number of Mucormycosis - - - ? - ? ? CM ? 140 - - - 140 5 patients with HIV/AIDS and respiratory diseases. PCP - 1,120 ? ? - 1,120 41 Histoplasmosis ? ? ? - - ? ? Results Fungal keratitis ? - - - - - ? Tinea capitis ? - - - - ? ? The Jamaican population was estimated to be 2,719,000 million Total burden 42,885+ 3,990+ 30,360 95+ 61+ 77,391+ people (2009), of whom 29% are children (0-14 years) and 11% are estimated >60 years old. The adult asthma population was estimated at 522,000. ABPA = Allergic bronchopulmonary aspergillosis, CM = Cryptococcal meningitis, PCP = Pneumocystis jirovecii Using a 2.5% rate of ABPA based on other studies (Denning et al, pneumonia, IA = Invasive aspergillosis, CPA = Chronic pulmonary aspergillosis, RVVC = Recurrent vaginal candidiasis, SAFS = Severe asthma with fungal sensitisation 2013), Jamaica has 13,000 ABPA cases and 17,225 SAFS cases (480 and, 633/100,000 respectively). Only 98 cases of pulmonary TB were reported in 2011, so chronic pulmonary aspergillosis is probably rare Conclusion with an estimated prevalence of 14 cases after TB (1/100.000), perhaps Using local data and literature, estimates of the incidence or prevalence 15% of the total CPA caseload. An estimated 42,885 women have 4 or of fungal infections, over 75,000 people in Jamaica probably suffer from more attacks of vaginal candidiasis annually (6% women >15 yrs, serious fungal infections each year, most related to asthma, recurrent based on a Nigerian rate) (3,154/100,000 females). Using a common vulvovaginal (RVVC) and HIV infection. Local epidemiological studies are international figure for candidaemia incidence of 5/100,000, 136 cases urgently required to validate or modify these estimates. of candidaemia occur each year, and 20 cases of Candida peritonitis in surgical patients. The burden HIV/AIDS is estimated to be 27,000+ patients, 1.6% of adults of whom (14,000) are not receiving References antiretroviral therapy (CD4 counts <350/uL). Assuming 50% and 15% 1. Bras G. Gordon CC, Emmons, CW Prendegast, KM & Sugar M. (1965) A case of phycomycosis observed in Jamaica; infection with Entomophthoracoronata. Amer. J. trop. Med. Hyg., 14: 141-145. of these patients develop oral or oesophageal candidiasis annually, 2. East-Innis A, Rainford L, Dunwell P, D Barrett-Robinson D, Nicholson AM (2006) The changing pattern of tinea capitis in Jamaica. West Indian Medical J 55: 85-88 6,300 and 2,100 cases respectively would be expected each year. 3. Fincharn AG, DeCeulaer K. (1980) Histoplasmin sensitivity among the cavers in Jamaica. West Indian Med J 29: 22- 27. Assuming 10% of those not on ARVs progress to a life-threatening 4. Fletcher CL, Moore MK, Hay RJ. (2001) Eumycetoma due to Madurellamycetomatis acquired in Jamaica. Br J Dermatol 145:1018-1021. opportunistic infections each year, and that the rate of PCP is 80% and 5. Nicholson AM, Rainford L, Elliott V, Christie CDC (2004). Disseminated histoplasmosis and AIDS at the University Hospital of the West Indies. West Indian Med J 53: 126-30. cryptococcal meningitis (CM) 10%, 1,120 PCP and 140 CM cases would 6. Barrow G, Ckarke TR, Carrington D, Harvey K, Barton EN. (2010). An Analysis of Three Opportunistic Infections in an Outpatient HIV Clinic in Jamaica. West Indian Med J 59: 393-399. be expected in AIDS annually. It wasn't possible to estimate the 7. Kahwa EK, Waldron NK, Younger NO, Edwards NC, Knight-Madden JM, Bailey KA, Wint YB, Lewis-Bell KN. Asthma and allergies in Jamaican children aged 2-17 years: a cross-sectional prevalence survey. BMJ Open. 2012 Jul 12;2(4). burden of histoplasmosis, invasive aspergillosis, mucormycosis, doi:pii: e001132. 8. Denning DW, Pleuvry A, Cole DC. Global burden of allergic bronchopulmonary aspergillosis with asthma and its mycetoma and fungal keratitis due to paucity of data. complication chronic pulmonary aspergillosis in adults. Med Mycol. 2013 May;51(4):361-70..
Load more

Recommended publications
  • Obligate Biotrophs of Humans and Other Mammals
    Pearls Genomic Insights into the Fungal Pathogens of the Genus Pneumocystis: Obligate Biotrophs of Humans and Other Mammals Philippe M. Hauser* Institute of Microbiology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland Pneumocystis organisms were first believed to be a single telomeres were not assembled. The nuclear genomes of the three protozoan species able to colonize the lungs of all mammals. Pneumocystis spp. are approximately 8 Mb. Subsequently, genetic analyses revealed their affiliation to the The mitochondrial genomes of P. murina and P. carinii are fungal Taphrinomycotina subphylum of the Ascomycota, a clade approximately 25 kb, whereas that of P. jirovecii is around 35 kb which encompasses plant pathogens and free-living yeasts. It also (Table 1). This size difference is due to a supplementary region that is appeared that, despite their similar morphological appearance, non-coding and highly variable in size and sequence among isolates these fungi constitute a family of relatively divergent species, each [5]. The circular structure of the P. jirovecii mitochondrial genome with a strict specificity for a unique mammalian species [1]. The differs from the linear one present in the two other Pneumocystis spp. species colonizing human lungs, Pneumocystis jirovecii, can turn The biological significance of this difference remains unknown. into an opportunistic pathogen that causes Pneumocystis pneu- monia (PCP) in immunocompromised individuals, a disease which Genome Content may be fatal. Although the incidence of PCP diminished in the 1990s thanks to prophylaxis and antiretroviral therapy, PCP is Using gene models specifically developed, the three Pneumo- nowadays the second-most-frequent, life-threatening, invasive cystis spp.
    [Show full text]
  • Rapid and Precise Diagnosis of Pneumonia Coinfected By
    Rapid and precise diagnosis of pneumonia coinfected by Pneumocystis jirovecii and Aspergillus fumigatus assisted by next-generation sequencing in a patient with systemic lupus erythematosus: a case report Yili Chen Sun Yat-Sen University Lu Ai Sun Yat-Sen University Yingqun Zhou First Peoples Hospital of Nanning Yating Zhao Sun Yat-Sen University Jianyu Huang Sun Yat-Sen University Wen Tang Sun Yat-Sen University Yujian Liang ( [email protected] ) Sun Yat-Sen University Case report Keywords: Pneumocystis jirovecii, Aspergillus fumigatus, Next generation sequencing, Case report Posted Date: March 19th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-154016/v2 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/12 Abstract Background: Pneumocystis jirovecii and Aspergillus fumigatus, are opportunistic pathogenic fungus that has a major impact on mortality in patients with systemic lupus erythematosus. With the potential to invade multiple organs, early and accurate diagnosis is essential to the survival of SLE patients, establishing an early diagnosis of the infection, especially coinfection by Pneumocystis jirovecii and Aspergillus fumigatus, still remains a great challenge. Case presentation: In this case, we reported that the application of next -generation sequencing in diagnosing Pneumocystis jirovecii and Aspergillus fumigatus coinfection in a Chinese girl with systemic lupus erythematosus (SLE). Voriconazole was used to treat pulmonary aspergillosis, besides sulfamethoxazole and trimethoprim (SMZ-TMP), and caspofungin acetate to treat Pneumocystis jirovecii infection for 6 days. On Day 10 of admission, her chest radiograph displayed obvious absorption of bilateral lung inammation though the circumstance of repeated fever had not improved.
    [Show full text]
  • 1. Economic, Ecological and Cultural Importance of Fungi
    1. Economic, ecological and cultural importance of Fungi Fungi as food Yeast fermentations, Saccaromyces cerevesiae [Ascomycota] alcoholic beverages, yeast leavened bread Glucose 2 glyceraldehyde-3-phosphate + 2 ATP 2 NAD O2 2 NADH2 2 pyruvate + 2 ATP + 2 H2O 2 ethanol 2 acetaldehyde + 2 ATP + 2 CO2 Fungi as food Citric acid Aspergillus niger Fungi as food Cheese Penicillium camembertii, Penicillium roquefortii Rennet, chymosin produced by Rhizomucor miehei and recombinant Aspergillus niger, Saccharomyces cerevesiae chymosin first GM enzyme approved for use in food Fungi as food Quorn mycoprotein, produced from biomass of Fusarium venenatum [Ascomycota] Fungi as food Red yeast rice, Monascus purpureus Soy fermentations, Aspergillus oryzae [Ascomycota] contains lovastatin? Tempeh, made with Rhizopus oligosporus [Zygomycota] Fungi as food Other fungal food products: vitamins and enzymes • vitamins: riboflavin (vitamin B2), commercially produced by Ashbya gossypii • chocolate: cacao beans fermented before being made into chocolate with a mixture of yeasts and filamentous fungi: Candida krusei, Geotrichum candidum, Hansenula anomala, Pichia fermentans • candy: invertase, commercially produced by Aspergillus niger, various yeasts, enzyme splits disaccharide sucrose into glucose and fructose, used to make candy with soft centers • glucoamylase: Aspergillus niger, used in baking to increase fermentable sugar, also a cause of “baker’s asthma” • pectinases, proteases, glucanases for clarifying juices, beverages Fungi as food Perigord truffle, Tuber
    [Show full text]
  • Outcome and Prognostic Factors of Pneumocystis Jirovecii Pneumonia
    Gaborit et al. Ann. Intensive Care (2019) 9:131 https://doi.org/10.1186/s13613-019-0604-x RESEARCH Open Access Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study Benjamin Jean Gaborit1,6* , Benoit Tessoulin2, Rose‑Anne Lavergne3, Florent Morio3, Christine Sagan4, Emmanuel Canet5, Raphael Lecomte1, Paul Leturnier1, Colin Deschanvres1, Lydie Khatchatourian1, Nathalie Asseray1, Charlotte Garret5, Michael Vourch5, Delphine Marest5, François Raf1, David Boutoille1,6 and Jean Reignier5 Abstract Background: Pneumocystis jirovecii pneumonia (PJP) remains a severe disease associated with high rates of invasive mechanical ventilation (MV) and mortality. The objectives of this study were to assess early risk factors for severe PJP and 90‑day mortality, including the broncho‑alveolar lavage fuid cytology profles at diagnosis. Methods: We prospectively enrolled all patients meeting pre‑defned diagnostic criteria for PJP admitted at Nantes university hospital, France, from January 2012 to January 2017. Diagnostic criteria for PJP were typical clinical features with microbiological confrmation of P. jirovecii cysts by direct examination or a positive specifc quantitative real‑time polymerase chain reaction (PCR) assay. Severe PJP was defned as hypoxemic acute respiratory failure requiring high‑ fow nasal oxygen with at least 50% FiO2, non‑invasive ventilation, or MV. Results: Of 2446 respiratory samples investigated during the study period, 514 from 430 patients were positive for P. jirovecii. Of these 430 patients, 107 met criteria for PJP and were included in the study, 53 (49.5%) patients had severe PJP, including 30 who required MV. All patients were immunocompromised with haematological malignancy ranking frst (n 37, 35%), followed by solid organ transplantation (n 27, 25%), HIV‑infection (n 21, 20%), systemic diseases (n 13,= 12%), solid tumors (n 12, 11%) and primary immunodefciency= (n 6, 8%).
    [Show full text]
  • Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments
    pathogens Review Pneumocystis Pneumonia: Immunity, Vaccines, and Treatments Aaron D. Gingerich 1,2, Karen A. Norris 1,2 and Jarrod J. Mousa 1,2,* 1 Center for Vaccines and Immunology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA; [email protected] (A.D.G.); [email protected] (K.A.N.) 2 Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA * Correspondence: [email protected] Abstract: For individuals who are immunocompromised, the opportunistic fungal pathogen Pneumocystis jirovecii is capable of causing life-threatening pneumonia as the causative agent of Pneumocystis pneumonia (PCP). PCP remains an acquired immunodeficiency disease (AIDS)-defining illness in the era of antiretroviral therapy. In addition, a rise in non-human immunodeficiency virus (HIV)-associated PCP has been observed due to increased usage of immunosuppressive and im- munomodulating therapies. With the persistence of HIV-related PCP cases and associated morbidity and mortality, as well as difficult to diagnose non-HIV-related PCP cases, an improvement over current treatment and prevention standards is warranted. Current therapeutic strategies have pri- marily focused on the administration of trimethoprim-sulfamethoxazole, which is effective at disease prevention. However, current treatments are inadequate for treatment of PCP and prevention of PCP-related death, as evidenced by consistently high mortality rates for those hospitalized with PCP. There are no vaccines in clinical trials for the prevention of PCP, and significant obstacles exist that have slowed development, including host range specificity, and the inability to culture Pneumocystis spp. in vitro. In this review, we overview the immune response to Pneumocystis spp., and discuss current progress on novel vaccines and therapies currently in the preclinical and clinical pipeline.
    [Show full text]
  • COVID-19 Pneumonia: the Great Radiological Mimicker
    Duzgun et al. Insights Imaging (2020) 11:118 https://doi.org/10.1186/s13244-020-00933-z Insights into Imaging EDUCATIONAL REVIEW Open Access COVID-19 pneumonia: the great radiological mimicker Selin Ardali Duzgun* , Gamze Durhan, Figen Basaran Demirkazik, Meltem Gulsun Akpinar and Orhan Macit Ariyurek Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread worldwide since December 2019. Although the reference diagnostic test is a real-time reverse transcription-polymerase chain reaction (RT-PCR), chest-computed tomography (CT) has been frequently used in diagnosis because of the low sensitivity rates of RT-PCR. CT fndings of COVID-19 are well described in the literature and include predominantly peripheral, bilateral ground-glass opacities (GGOs), combination of GGOs with consolida- tions, and/or septal thickening creating a “crazy-paving” pattern. Longitudinal changes of typical CT fndings and less reported fndings (air bronchograms, CT halo sign, and reverse halo sign) may mimic a wide range of lung patholo- gies radiologically. Moreover, accompanying and underlying lung abnormalities may interfere with the CT fndings of COVID-19 pneumonia. The diseases that COVID-19 pneumonia may mimic can be broadly classifed as infectious or non-infectious diseases (pulmonary edema, hemorrhage, neoplasms, organizing pneumonia, pulmonary alveolar proteinosis, sarcoidosis, pulmonary infarction, interstitial lung diseases, and aspiration pneumonia). We summarize the imaging fndings of COVID-19 and the aforementioned lung pathologies that COVID-19 pneumonia may mimic. We also discuss the features that may aid in the diferential diagnosis, as the disease continues to spread and will be one of our main diferential diagnoses some time more.
    [Show full text]
  • Mucormycosis of the Central Nervous System
    Journal of Fungi Review Mucormycosis of the Central Nervous System 1 1,2, , 3, , Amanda Chikley , Ronen Ben-Ami * y and Dimitrios P Kontoyiannis * y 1 Infectious Diseases Unit, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel 2 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 64239, Israel 3 Department of Infectious Diseases, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA * Correspondence: [email protected] (R.B.-A.); [email protected] (D.P.K.) These authors contribute equally to this paper. y Received: 6 June 2019; Accepted: 7 July 2019; Published: 8 July 2019 Abstract: Mucormycosis involves the central nervous system by direct extension from infected paranasal sinuses or hematogenous dissemination from the lungs. Incidence rates of this rare disease seem to be rising, with a shift from the rhino-orbital-cerebral syndrome typical of patients with diabetes mellitus and ketoacidosis, to disseminated disease in patients with hematological malignancies. We present our current understanding of the pathobiology, clinical features, and diagnostic and treatment strategies of cerebral mucormycosis. Despite advances in imaging and the availability of novel drugs, cerebral mucormycosis continues to be associated with high rates of death and disability. Emerging molecular diagnostics, advances in experimental systems and the establishment of large patient registries are key components of ongoing efforts to provide a timely diagnosis and effective treatment to patients with cerebral mucormycosis. Keywords: central nervous system; mucormycosis; Mucorales; zygomycosis 1. Introduction Mucormycosis is the second most frequent invasive mold disease after aspergillosis [1–3], with rising incidence reported in some countries [4–7].
    [Show full text]
  • The Diagnostic Challenge of Pneumocystis Pneumonia and COVID-19 Co-Infection in HIV Alistair G.B
    Official Case Reports Journal of the Asian Pacific Society of Respirology Respirology Case Reports The diagnostic challenge of pneumocystis pneumonia and COVID-19 co-infection in HIV Alistair G.B. Broadhurst1 , Usha Lalla2, Jantjie J. Taljaard3, Elizabeth H. Louw2, Coenraad F.N. Koegelenberg2 & Brian W. Allwood2 1Division of General Medicine, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. 2Division of Pulmonology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. 3Division of Infectious Diseases, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa. Keywords Abstract COVID-19, HIV, pneumocystis pneumonia, SARS- CoV-2. Coronavirus disease 2019 (COVID-19) and pneumocystis pneumonia (PCP) share many overlapping features and may be clinically indistin- Correspondence guishable on initial presentation in people living with HIV. We present Alistair G.B. Broadhurst, Division of General Medicine, the case of co-infection with COVID-19 and PCP in a patient with pro- DepartmentofMedicine,FacultyofMedicineand gressive respiratory failure admitted to our intensive care unit where the Health Sciences, Stellenbosch University and Tygerberg dominant disease was uncertain. This case highlights the difficulty in dif- Hospital, Francie van Zijl Drive, 7505 Cape Town, South Africa. E-mail: [email protected] ferentiating between the two diseases, especially in a high HIV preva- lence setting where PCP is frequently diagnosed using case definitions Received: 29 September 2020; Accepted: 3 February and clinical experience due to limited access to bronchoscopy, appropri- 2021; Associate Editor: Charles Feldman.
    [Show full text]
  • GAFFI Fact Sheet Pneumocystis Pneumonia
    OLD VERSION GLOBAL ACTION FUNDGAL FOR INFECTIONS FUN GAFFI Fact Sheet Pneumocystis pneumonia GLOBAL ACTION FUNDGAL FOR INFECTIONS Pneumocystis pneumonia (PCP) is a life-threatening illness of largely FUN immunosuppressed patients such as those with HIV/AIDS. However, when diagnosed rapidly and treated, survival rates are high. The etiologic agent of PCP is DARKER AREAS AND SMALLER VERSION TEXT FIT WITHIN CIRCLE (ALSO TO BE USED AS MAIN Pneumocystis jirovecii, a human only fungus that has co-evolved with humans. Other LOGO IN THE FUTURE) mammals have their own Pneumocystis species. Person to person transmission occurs early in life as demonstrated by antibody formation in infancy and early childhood. Some individuals likely clear the fungus completely, while others become carriers of variable intensity. About 20% of adults are colonized but higher colonization rates occur in children and immunosuppressed adults; ethnicity and genetic associations with colonization are poorly understood. Co-occurrence of other respiratory infections may provide the means of transmission in most instances. Patients with Pneumocystis pneumonia (PCP) are highly infectious. Prophylaxis with oral cotrimoxazole is highly effective in preventing infection. Pneumocystis pneumonia The occurrence of fatal Pneumocystis pneumonia in homosexual men in the U.S. provided one of earliest signals of the impending AIDS epidemic in the 1980s. Profound immunosuppression, especially T cell depletion and dysfunction, is the primary risk group for PCP. Early in the AIDS epidemic, PCP was the AIDS-defining diagnosis in ~60% of individuals. This frequency has fallen in the western world, but infection is poorly documented in most low-income countries because of the lack of diagnostic capability.
    [Show full text]
  • HIV Awareness in the Workplace Online Nursing CE Course
    Online Continuing Education for Nurses Linking Learning to Performance INSIDE THIS COURSE HIV AIDS 7 UNIT: HIV AWARENESS COURSE OUTLINE ............................ 2 IN THE WORKPLACE CHAPTER 1: HIV AIDS DEFINED ...... 3 CHAPTER 2: WORKPLACE 7.0 Contact Hours PROTECTION ................................. 11 0.7 Continuing Education Units CHAPTER 3: PATIENT CARE AND RIGHTS ......................................... 14 Written by: Robert Dunham, RMA CHAPTER 4: TUBERCULOSIS ........... 21 Objectives REFERENCES ................................ 29 CE EXAM...................................... 31 After completing HIV Awareness in the EVALUATION ................................. 38 Workplace, you will be able to: 1. Define HIV/AIDS including origin, etiology and epidemiology of HIV. 2. Understand how HIV/AIDS is transmitted and effective methods of infection control and prevention. 3. Discuss contamination myths and practice safe workplace habits to minimize workplace exposure. 4. Identify legal/ethical issues and patient rights surrounding HIV/AIDS. 5. Support patients with HIV/AIDS by providing accurate information and counseling when necessary. 6. Identify tuberculosis and how it impacts immune compromised patients. 7. Understand how medical facilities are taking steps to prevent tuberculosis in the workplace. 8. Understand how the World Health Organization is helping HIV patients with tuberculosis around the world, and how it impacts new defensive medicine techniques. Robert Dunham, RMA www.corexcel.com Page 2 HIV Awareness in the Workplace COURSE OUTLINE I. Etiology and epidemiology of HIV 1. Etiology 2. Reported AIDS cases in the United States and Washington State 3. Risk populations/behaviors II. Transmission and infection control 1. Transmission of HIV 2. Infection Control Precautions 3. Factors affecting risk for transmission 4. Risks for transmission to health care worker III. Testing and counseling 1.
    [Show full text]
  • Superficial Fungal Infection
    Infeksi jamur superfisial (mikosis superfisialis) R. Wahyuningsih Dep. Parasitologi FK UKI 31 Maret 2020 Klasifikasi mikosis superfisialis berdasarkan penyebab • Dermatofitosis • kandidiasis superfisialis • Infeksi Malassezia/panu M. Raquel Vieira, ESCMID Dermatofitosis • Infeksi jaringan keratin (kulit, kuku & rambut) oleh jamur filamen gol. dermatofita • genus dermatofita – Tricophyton, – Microsporum – Epidermophyton, • ± 10 spesies menyebabkan dermatofitosis pada manusia Asian incidence of the most common mycoses identified All values are percentages In Asia, T. rubrum and T. mentagrophytes are the most commonly isolated pathogens, causing tinea pedis and unguium, as is the case in Europe. Havlickova et al, Mycoses Dermatophytosis di Indonesia • Geofilik: M . gypseum • Zoofilik: M. canis • Antropofilik: – T. rubrum – T. concentricum – E. floccosum Patologi & organ terinfeksi Kuku kulit rambut Trichophyton + + + Microsporum + + + Epidermophyton + + - http://www.njmoldinspection.com/mycoses/moldinfections.html Dermatophytoses...... • Gejala klinik tergantung pada: • Lokalisasi infeksi • Respons imun pejamu • Spesies jamur • Lesi: karakteristik (ring worm) tetapi dalam kondisi imuno supresi menjadi tidak khas perlu pemeriksaan laboratorium Dermatofita & dermatofitosis T. rubrum: biakan. kapang, pigmen merah, mikrokonidia lonjong, tetesan air mata/anggur, makrokonidia seperti pinsil/cerutu . antropofilik, . kelainan kronik mis. • tinea kruris, onikomiksosis De Berker, N Engl J Med 2009;360:2108-16 Dermatofita & dermatofitosis M. canis
    [Show full text]
  • Human and Microbial Proteins from Corpora Amylacea of Alzheimer's
    www.nature.com/scientificreports OPEN Human and Microbial Proteins From Corpora Amylacea of Alzheimer’s Disease Received: 24 November 2017 Diana Pisa1, Ruth Alonso1, Ana Isabel Marina1, Alberto Rábano2 & Luis Carrasco1 Accepted: 14 June 2018 Corpora amylacea (CA) are spherical bodies mainly composed of polyglucans and, to a lesser extent, Published: xx xx xxxx proteins. They are abundant in brains from patients with neurodegenerative diseases, particularly Alzheimer’s disease. Although CA were discovered many years ago, their precise origin and function remain obscure. CA from the insular cortex of two Alzheimer’s patients were purifed and the protein composition was assessed by proteomic analysis. A number of microbial proteins were identifed and fungal DNA was detected by nested PCR.A wide variety of human proteins form part of CA. In addition, we unequivocally demonstrated several fungal and bacterial proteins in purifed CA. In addition to a variety of human proteins, CA also contain fungal and bacterial polypeptides.In conclusion, this paper suggests that the function of CA is to scavenge cellular debris provoked by microbial infections. Several diferent types of polyglucan bodies have been found in the central nervous system (CNS) of elderly peo- ple, as well as in patients with a variety of pathologies, including Alzheimer’s disease (AD), epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS) and hippocampal sclerosis1,2. Among these polyglucan structures, Lafora bodies, Bielschowsky bodies and corpora amylacea (CA) have been identifed based on their morphological characteristics3–5. Although CA were described early in the 18th century, their precise origin and potential function in normal or pathological conditions remains an enigma.
    [Show full text]